A Three-part, Phase I/II Dose-Escalation Study to Define the Safety, Tolerability, and Optimal Dose of Candidate GBM vaccine VBI-1901 with Subsequent Extension of Optimal Dose in Recurrent GBM subjects.

The purpose of this study is to test the safety of a new vaccine, VBI-1901, and to know more about it's ability to boost the response of the immune system against Cytomegalovirus. The reason for testing this vaccine in people with a brain tumor is that it might one day be used to boost the ability of the immune system to fight a certain type of brain tumor. This type of treatment for brain tumors is called immunotherapy.

Are you Eligible? (Inclusion Criteria)

• Participants must:
• 1. Be 18 - 70 years of age
• 2. Have histologically confirmed WHO grade IV glioblastoma
• 3. Have unequivocal evidence of a tumor recurrence (any number of
• recurrences) or progression after an initial treatment regimen (prior to
• enrollment on this study)
• 4. Have recovered from the effects of surgery